Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS researchers receive awards from the NSTF
2008-06-04

The recipients of the two awards are, from the left: Prof. Jan van der Westhuizen, UFS Department of Chemistry, Dr Susan Bonnet, UFS Department of Chemistry, Prof. Thinus van der Merwe, FARMOVS-PAREXEL, Prof. Maryke Labuschagne, UFS Department of Plant Sciences, and Prof. Ken Swart, FARMOVS-PAREXEL.
Photo: Lacea Loader

  

UFS researchers receive awards from the NSTF   

The University of the Free State (UFS) last week received two prestigious awards from the National Science and Technology Forum (NSTF) during its tenth gala-awards ceremony held in Kempton Park.

Prof. Maryke Labuschagne from the Department of Plant Sciences at the UFS was the female recipient of the research capacity-development award over the last ten years. She received the award for her successful mentoring of black researchers and students. The award, sponsored by Eskom, includes a prize of R100 000 which will be used for research purposes.  

A team consisting of Prof. Jan van der Westhuizen and Dr Susan Bonnet from the Department of Chemistry at the UFS and Prof. Kenneth Swart and Prof. Thinus van der Merwe from FARMOVS–PAREXEL received the innovation award for an outstanding contribution to science, engineering and technology from either an individual or a team over the last ten years.
 
Prof. Labuschagne, an expert in the field of plant breeding and food security in Africa, received the award for her contribution to the training and development of black students and researchers in this field. Various black students successfully completed their postgraduate studies under her guidance at the UFS during the past ten years, with positive results.

Research by her South African students has led to a firmly entrenched research relationship between the Agricultural Research Council (ARC) and the UFS, while research by her local and international students has culminated in no less than 82 publications over the last decade.

It has also led to the establishment of collaboration agreements with universities and research institutes in Malawi, Kenya, Uganda and Tanzania – among others with the University of Malawi where Prof. Labuschagne and her students are involved in the International Programme in the Chemical Sciences (IPICS) of the Uppsala University in Sweden. The project focuses on the study of genetics and chemistry of tropical roots and tuber crops in Malawi. This has led to collaboration with international research organisations and has generated overseas funding.

The combined team from FARMOVS–PAREXEL and the UFS won an award for the synthesis of drug analogues used as reference products during the analysis of the drug concentration in blood, from existing and new drugs registered nationally and internationally.

The project resulted in capacity building in synthetic organic chemistry, mass spectrometry and chromatography: Five master’s degrees were completed, seven are in progress, and six postgraduate students commenced with Ph.D.’s.

The skills transferred during this project are already being applied to examine the properties of indigenous medicinal plants as part of the recently established UFS novel drugs and bioactive compound cluster.

Applied Biosystems, the Canadian manufacturer of mass spectrometers, donated equipment to the value of more than R10 million for this project. As a result the UFS is one of the few universities in the world that can offer postgraduate training in bioanalytical chemistry.

Prof. Hendrik Swart, head of the Department of Physics at the UFS, and Dr Martin Ntwaeaborwa, senior lecturer at the Department of Physics were finalist in the research- capacity developer and black-researcher categories respectively.
The NSTF awards gives recognition to the outstanding contributions of individuals and groups to science, engineering and technology. This includes all practising scientists, engineers and technologists across the system of innovation, including, for example, teachers and students in mathematics, science and technology. The NSTF represents government, science councils, professional bodies, higher education, business and civil society.

Altogether nine individuals and three organisations were presented with the NSTF Awards trophy by the Minister of Science and Technology, Mr Mosibudi Mangena.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel:  051 401 2584
Cell:  083 645 2454
E-mail:  loaderl.stg@ufs.ac.za
4 June 2008

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept